BIOVIE INC

Biovie Inc (BIVI) is a micro‑cap biopharmaceutical company with a market capitalisation of roughly $14.4 million. Like many small biotech firms, it appears to derive value largely from its research and development pipeline rather than recurring commercial revenue. Investors should expect that valuation will be sensitive to clinical updates, regulatory developments and financing activity. Small market caps often mean limited liquidity, wider bid‑ask spreads and higher share‑price volatility. Key considerations include clinical and regulatory risk, the potential for equity dilution if management raises capital, and typically limited analyst coverage or public information. For further due diligence, review the company’s financial filings, press releases, investor presentations and any clinical trial registrations. This summary is educational only and is not financial advice; it is most relevant to investors who understand and accept high-risk, speculative investments rather than those seeking income or capital preservation.